- Home
- BDRX vs QLGN Comparison
BDRX vs QLGN Comparison
Compare BDRX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- QLGN
- Stock Information
- Founded
- BDRX 2000
- QLGN 1996
- Country
- BDRX United Kingdom
- QLGN United States
- Employees
- BDRX N/A
- QLGN N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- QLGN Health Care
- Exchange
- BDRX Nasdaq
- QLGN Nasdaq
- Market Cap
- BDRX 2.4M
- QLGN 2.4M
- IPO Year
- BDRX N/A
- QLGN N/A
- Fundamental
- Price
- BDRX $1.33
- QLGN $3.41
- Analyst Decision
- BDRX
- QLGN
- Analyst Count
- BDRX 0
- QLGN 0
- Target Price
- BDRX N/A
- QLGN N/A
- AVG Volume (30 Days)
- BDRX 3.5M
- QLGN 111.5K
- Earning Date
- BDRX 04-21-2025
- QLGN 04-15-2025
- Dividend Yield
- BDRX N/A
- QLGN N/A
- EPS Growth
- BDRX N/A
- QLGN N/A
- EPS
- BDRX N/A
- QLGN N/A
- Revenue
- BDRX $104,895.00
- QLGN N/A
- Revenue This Year
- BDRX N/A
- QLGN N/A
- Revenue Next Year
- BDRX N/A
- QLGN N/A
- P/E Ratio
- BDRX N/A
- QLGN N/A
- Revenue Growth
- BDRX N/A
- QLGN N/A
- 52 Week Low
- BDRX $1.14
- QLGN $2.96
- 52 Week High
- BDRX $74.00
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- BDRX 35.57
- QLGN 51.52
- Support Level
- BDRX $1.14
- QLGN $3.09
- Resistance Level
- BDRX $2.65
- QLGN $3.78
- Average True Range (ATR)
- BDRX 0.24
- QLGN 0.28
- MACD
- BDRX 0.01
- QLGN 0.05
- Stochastic Oscillator
- BDRX 26.49
- QLGN 39.60
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.